Bhel

BHEL Consolidated December 2025 Net Sales at Rs 8,473.10 crore, up 16.44% Y-o-Y

Hold BHEL; target of Rs 245: Prabhudas Lilladher

Prabhudas Lilladher recommended hold rating on BHEL with a target price of Rs 245 in its research report dated January 19, 2026.

BHEL shares fall 4% as brokerages say Q3 gross margins drag on earnings

Domestic brokerage JM Financial said BHEL's current focus on completion of 10.2 GW of pre-Talcher projects in 2026 is impacting margins

BHEL Standalone December 2025 Net Sales at Rs 8,473.10 crore, up 16.44% Y-o-Y

BHEL reports 3-fold jump in net profit to Rs 390 crore in Q3

BHEL achieved a revenue of Rs 2,150.74 crore in October-December, up from Rs 1,688.64 crore in the year-ago period.

China will raise competition for BHEL, but unlikely to hurt its business significantly

Investors would do well to focus on execution of order backlog at BHEL

BHEL Standalone September 2025 Net Sales at Rs 7,511.80 crore, up 14.09% Y-o-Y

Buy BHEL; target of Rs 250: Prabhudas Lilladher

Prabhudas Lilladher is bullish on BHEL has recommended buy rating on the stock with a target price of Rs 250 in its research report dated October 30, 2025.

BHEL Consolidated September 2025 Net Sales at Rs 7,511.80 crore, up 14.09% Y-o-Y

BHEL to develop fuel cell-based trains in partnership with Singapore-based Horizon Tech

A hydrogen fuel cell-based rolling stock uses on-board hydrogen fuel cells to generate electricity, and is a zero-emission alternative to diesel or electric trains.

Hold BHEL; target of Rs 215: Prabhudas Lilladher

Prabhudas Lilladher recommended hold rating on BHEL with a target price of Rs 215 in its research report dated August 07, 2025.

BHEL Standalone June 2025 Net Sales at Rs 5,486.91 crore, up 0.04% Y-o-Y

BHEL shares fall over 6 percent as CLSA recommends 'Underperform' after net loss doubles

Bharat Heavy Electricals (BHEL) said its net loss more than doubled to Rs 455.50 crore in the June quarter mainly due to higher expenses, compared to a net loss of Rs 211.40 crore a year ago.

UBS initiates coverage on BHEL, Waaree, Suzlon, Premier Energies; sees up to 40% upside

UBS kicked off coverage with a ‘buy’ rating on power generation players BHEL, Waaree Energies, Premier Energies, and Suzlon Energy.

BHEL shares jump 3% to hit 6-month high after firm wins Rs 6,500-crore order from Adani Power

BHEL share price: BHEL shares opened at Rs 272 apiece, the highest level seen by the stock in nearly 6 months.

Stocks to Watch Today: Torrent Pharma, JB Chemicals, Jyoti CNC, BHEL, Alembic Pharma, Waaree Energies, Prestige Estates, Hind Rectifiers in focus on 30 June

Stocks to Watch, 30 June: Stocks like Torrent Pharmaceuticals, JB Chemicals and Pharmaceuticals, Jyoti CNC Automation, BHEL, Alembic Pharma, Waaree Energies, Prestige Estates Projects, Bharti Airtel, Le Lavoir, Reliance Industries, and Hind Rectifiers will be in focus on June 30.

Smallcap, midcap stocks rise up to 15%, broader market indices extend gains for second day; check top gainers

BEML shares were the top gainer on the smallcap index, rallying over 15 percent to close at Rs 4,294.60 apiece.

Hold BHEL; target of Rs 237: Prabhudas Lilladher

Prabhudas Lilladher recommended hold rating on BHEL with a target price of Rs 237 in its research report dated May 20, 2025.

Chart of the Day: BHEL’s record order book faces a moment of reckoning

The company saw record order inflows for second consecutive year in FY25

BHEL Consolidated March 2025 Net Sales at Rs 8,993.37 crore, up 8.88% Y-o-Y

BHEL Standalone March 2025 Net Sales at Rs 8,993.37 crore, up 8.88% Y-o-Y

BHEL Q4 results: Net profit rises 4% to Rs 504 crore, firm declares dividend

BHEL Q4 results: Revenue jumps 9% to Rs 8,993 crore

Defence stocks gain on escalating India-Pakistan tension; Paras Defence, Zen Technologies soar up to 6%

On May 8, shares of defence companies tumbled in the second half amidst profit booking with most defence players losing early gains.

BHEL shares slip 5% after Ducon Tech initiates arbitration against firm

Stocks To Watch: Alembic Pharma, BHEL, Zydus Life, Wipro In Focus | February 17

In today's stock market update for February 17, we highlight key stocks to watch: Wipro, which appointed Amit Kumar as Managing Partner and Global Head of Consulting; BHEL, which secured a Letter of Intent for a thermal power project; and Alembic Pharma, which received a Voluntary Action Indicated classification from the US FDA for its Jarod facility. Zydus Lifesciences passed a successful US FDA inspection with no observations at its Ambernath site. Meanwhile, Ujjivan Small Finance Bank and Shriram Finance face RBI penalties for non-compliance with loan and KYC regulations. Stay tuned for more market insights!